Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE versus THIOSULFIL.
SULFAMETHOXAZOLE vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Trovafloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfamethoxazole + Nalidixic acid
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Nalidixic acid."